Compare Becton Dickinson and Co (BDX) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Virgin Galactic Holdings, Inc. — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Virgin Galactic Holdings, Inc. trades at $2.61 (market cap $335.48M). The key difference: Becton Dickinson and Co is far larger — about 123.7× Virgin Galactic Holdings, Inc.'s market cap, and Becton Dickinson and Co pays a 2.79% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals.
| BDX | SPCE | |
|---|---|---|
Market Cap | $41.51B | $335.48M |
Sector | Health | Industrials |
52-Week High | $185.39 | $7.52 |
52-Week Low | $135.49 | $2.17 |
Enterprise Value | $57.97B | $435.33M |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
SPCE trades at $2.42, down 5.84% over 24 hours, reflecting ongoing volatility amid negative profitability. The company reported a net loss of $278.91 million on minimal revenue of $1.54 million in 2025, with cash burn persisting despite narrowing losses. Technical indicators are mixed, with a bearish moving average signal but oversold RSI levels, while analyst consensus is divided with a slight hold bias.
The outlook remains speculative, with opportunities tied to future commercial spaceflight execution, but risks are elevated due to persistent losses, high cash burn, and significant debt. Investor sentiment is cautious, driven by the unproven business model and competitive pressures in the space sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
